Diligence report Healthcare & Life Sciences / regulated AI digital health platform Private unicorn / Series D

Huma

Startup Unicorn Diligence Research Report: Huma

The diligence case depends on whether Huma can convert a regulated AI health platform and pharma/health-system traction into defensible recurring revenue while maintaining clinical, regulatory, privacy and model-governance controls across jurisdictions.

Company profile

Startup Unicorn Diligence Research Report: Huma

Huma is publicly supportable as an active UK private unicorn with a CB Insights $1B valuation anchor, over $80M of 2024 Series D-related issuance, over $300M raised to date and substantial public product/regulatory claims. Highest-priority diligence issues are financial opacity, regulated SaMD/AI compliance, customer concentration and whether public scale metrics translate into durable recurring revenue.

Website: www.huma.com
Sector: Healthcare & Life Sciences / regulated AI digital health platform
Geography: United Kingdom headquartered; global healthcare, pharma and research deployments
Stage: Private unicorn / Series D
Known aliases: Huma Therapeutics Limited, Medopad Ltd, Huma Therapeutics, Huma Cloud Platform, Huma Workspace, Huma Intelligence, GDm Health
Report version: 1.0
Timezone: Europe/London

Executive summary

Strengths

Huma is active as a UK private limited company and appears on CB Insights unicorn list at a $1B valuation.
Huma announced over $80M Series D-related issuance and over $300M raised to date.
Public Huma pages support a regulated digital health platform narrative with FDA Class II and product evidence.

Risks

Audited financial quality, ARR, margins and runway are not public.
Regulated SaMD and AI workflows create compliance and clinical-safety obligations.
Customer concentration, contract quality, retention and procurement exposure are not public.

Gaps

Audited financials, ARR, gross margin, cash runway, AR aging and backlog.
Current cap table, preference stack, debt, warrants, options and investor rights.
Customer-level revenue, renewals, churn, NRR and contract terms.
Regulatory clearance scope, QMS audits and agency correspondence.
AI model validation, bias testing, production status and model ownership.
Headcount by function/location, attrition, compensation and hiring plan.

Recommended next steps

Open finance and cap-table data rooms before relying on the public $1B valuation anchor.
Reconcile deployment metrics to active contracts, revenue, retention, gross margin and customer references.
Have regulatory and privacy counsel review SaMD scope, QMS, post-market surveillance, AI governance and data-protection controls.
Run win/loss diligence against RPM, digital-trial and health-AI platform competitors.

Risk register

high high likelihood

R-001: Opaque financial statements and unit economics

Audited financials, ARR quality, margins and runway are not public.

Diligence request: Request audited statements, KPI definitions, monthly accounts and runway bridge.

high medium likelihood

R-002: Valuation and preference-stack risk

The $1B valuation anchor is public, but private round terms, debt and dilution are not.

Diligence request: Review cap table, financing documents and liquidation waterfall.

high medium likelihood

R-003: Regulated SaMD compliance exposure

FDA/EU/UK/Saudi regulated software claims imply ongoing QMS, labeling and post-market obligations.

Diligence request: Regulatory counsel review of clearance scope and change control.

high medium likelihood

R-004: Clinical evidence and safety validation risk

Deployment metrics do not replace product-specific clinical outcomes and safety evidence.

Diligence request: Obtain clinical dossiers, complaints, adverse events and outcome data.

high medium likelihood

R-005: Health data privacy and security exposure

Health data, AI and device integrations create cross-border privacy/security risk.

Diligence request: Review DPIAs, subprocessors, incidents, pen tests and DPAs.

high medium likelihood

R-008: AI model performance and liability risk

AI algorithm hosting and automation require model governance, bias controls and liability allocation.

Diligence request: Review model validation, monitoring and contracts.

medium high likelihood

R-006: Customer concentration and procurement-cycle risk

Public deployment and partner claims do not disclose customer revenue, renewal or churn.

Diligence request: Request top-customer schedules, contracts and references.

medium high likelihood

R-007: Competitive differentiation risk

Huma operates across crowded RPM, trials and health-AI categories.

Diligence request: Run win/loss, pricing and technical benchmarking.

Chapter 01

01Financial Information

Public sources verify financing and valuation anchors but not audited financials, ARR, margins, runway or cap-table economics.

EC-013 EC-004 EC-012 EC-019 EC-010 EC-014 EC-002 EC-003

I.A Annual and quarterly financial information for the past three years

not publicly verifiable confidence: high

Public-source diligence for annual and quarterly financial information for the past three years is summarized with 1 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-013 EC-004 EC-012 EC-019

Evidence gaps

Company-provided source documents are required for checklist area I.A: Annual and quarterly financial information for the past three years.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for annual and quarterly financial information for the past three years.

Follow-up questions

Provide dated data-room materials covering annual and quarterly financial information for the past three years, with source-system exports where applicable.

Public financial and operating signals
metric	public signal	status	request
Revenue	Doubled year-on-year; targeting profitability	partially_verified	Audited revenue, ARR, gross margin
Scale	3,000+ hospitals/clinics; 140,000 contracted lives	partially_verified	Active contracts and revenue
Financial statements	Not public	not_publicly_verifiable	Financials, AR aging, backlog, cash runway

I.B Financial Projections

not publicly verifiable confidence: high

Public-source diligence for financial projections is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-013 EC-010 EC-014

Evidence gaps

Company-provided source documents are required for checklist area I.B: Financial Projections.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for financial projections.

Follow-up questions

Provide dated data-room materials covering financial projections, with source-system exports where applicable.

I.C Capital Structure

not publicly verifiable confidence: high

Public-source diligence for capital structure is summarized with 1 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-002 EC-003 EC-019

Evidence gaps

Company-provided source documents are required for checklist area I.C: Capital Structure.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for capital structure.

Follow-up questions

Provide dated data-room materials covering capital structure, with source-system exports where applicable.

Capital structure and investor snapshot
stakeholder	public position	status	diligence request
AstraZeneca / HAT SGR / Hitachi Ventures / Leaps by Bayer	Series D investors named by Huma	verified	Rights, ownership and commercial links
Debt, options, warrants, preference stack	Not public	not_publicly_verifiable	Full cap table and waterfall

I.D Other financial information

partially verified confidence: medium

Public-source diligence for other financial information is summarized with 1 linked table(s) and 2 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-002 EC-003 EC-013

Evidence gaps

Company-provided source documents are required for checklist area I.D: Other financial information.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for other financial information.

Follow-up questions

Provide dated data-room materials covering other financial information, with source-system exports where applicable.

Public funding and valuation history
date	event	amount	verification status	diligence request
2024-07-16	Series D issuance	Over $80M; over $300M raised to date	verified	Round docs and terms
2024-07-16	CB Insights valuation	$1B	verified	Reconcile to cap table

Funding and corporate-status timeline Public financing and legal status events.

Public financing and valuation anchors Financing and valuation anchors.

Chapter 02

02Products

Public product evidence supports a regulated AI/digital health platform; pricing, margins and product usage require private evidence.

EC-005 EC-006 EC-007 EC-010

II.A Description of each product

partially verified confidence: medium

Public-source diligence for description of each product is summarized with 2 linked table(s) and 1 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-005 EC-006 EC-007 EC-010

Evidence gaps

Company-provided source documents are required for checklist area II.A: Description of each product.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for description of each product.

Follow-up questions

Provide dated data-room materials covering description of each product, with source-system exports where applicable.

Product and SKU matrix
product	audience	public description	status	request
Huma Cloud / Workspace	Health builders	No-code/SDK regulated platform	partially_verified	Usage, pricing and roadmap
Huma Intelligence	Clinicians	AI/scribing and structured data workflows	partially_verified	Model validation
A&E eTriage / GDm Health	Secondary care	Emergency triage and gestational diabetes products	partially_verified	Outcomes and contracts

Pricing and packaging diligence matrix
offer	public pricing	status	request
Huma Cloud / Workspace	No public price sheet found	not_publicly_verifiable	ARR, implementation fees, discounting, margin
Clinical trials / RWE	No public price sheet found	not_publicly_verifiable	Contract value and service margin

Huma platform architecture view Conceptual public architecture.

Chapter 03

03Customer Information

Public sources show deployment, user, research and partner signals, but customer revenue, concentration, retention and contract terms are not public.

EC-004 EC-011 EC-012 EC-003 EC-018 EC-014 EC-006 EC-010

III.A Top customers by application

partially verified confidence: medium

Public-source diligence for top customers by application is summarized with 1 linked table(s) and 1 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-004 EC-011 EC-012

Evidence gaps

Company-provided source documents are required for checklist area III.A: Top customers by application.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for top customers by application.

Follow-up questions

Provide dated data-room materials covering top customers by application, with source-system exports where applicable.

Public customers, deployments and case-study signals
customer or metric	public signal	status	request
3,000+ hospitals/clinics	Huma projects powered in hospitals/clinics	partially_verified	Active paid customers
Banner, NHS, Bayer, AstraZeneca, Servier	Public quotes/signals	partially_verified	Contracts and references
140,000 contracted lives	US respiratory RPM	partially_verified	Active lives and economics

Public scale metrics Public usage/deployment metrics.

III.B Strategic relationships

partially verified confidence: medium

Public-source diligence for strategic relationships is summarized with 1 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-003 EC-011 EC-018

Evidence gaps

Company-provided source documents are required for checklist area III.B: Strategic relationships.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for strategic relationships.

Follow-up questions

Provide dated data-room materials covering strategic relationships, with source-system exports where applicable.

Strategic relationships and partnerships
partner	nature	evidence	request
AstraZeneca / Bayer	Investors and public pharma signals	Series D and homepage	Commercial terms and concentration
Google and others	AI model development	Series D release	Data, model and IP terms

III.C Revenue by customer

not publicly verifiable confidence: high

Public-source diligence for revenue by customer is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-012 EC-014

Evidence gaps

Company-provided source documents are required for checklist area III.C: Revenue by customer.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for revenue by customer.

Follow-up questions

Provide dated data-room materials covering revenue by customer, with source-system exports where applicable.

III.D Significant relationships severed within the last two years

not publicly verifiable confidence: high

Public-source diligence for significant relationships severed within the last two years is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-014

Evidence gaps

Company-provided source documents are required for checklist area III.D: Significant relationships severed within the last two years.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for significant relationships severed within the last two years.

Follow-up questions

Provide dated data-room materials covering significant relationships severed within the last two years, with source-system exports where applicable.

III.E Top suppliers

partially verified confidence: medium

Public-source diligence for top suppliers is summarized with 1 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-006 EC-010 EC-018

Evidence gaps

Company-provided source documents are required for checklist area III.E: Top suppliers.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for top suppliers.

Follow-up questions

Provide dated data-room materials covering top suppliers, with source-system exports where applicable.

Supplier and integration dependencies
dependency	role	risk	request
Cloud hosting/API framework	Deployment infrastructure	Concentration and uptime unknown	Cloud contracts and architecture
Third-party devices	Vitals/device data	Validation and recall exposure	Device partner list and validation
AI model partners	Automation	Model and data dependency	Licenses and governance

Chapter 04

04Competition

Huma competes across RPM, digital therapeutics, clinical-trial/RWE platforms and regulated AI health infrastructure.

EC-010 EC-015

IV.A Competitive landscape by market segment

inconclusive confidence: low

Public-source diligence for competitive landscape by market segment is summarized with 2 linked table(s) and 1 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-010 EC-015

Evidence gaps

Company-provided source documents are required for checklist area IV.A: Competitive landscape by market segment.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for competitive landscape by market segment.

Follow-up questions

Provide dated data-room materials covering competitive landscape by market segment, with source-system exports where applicable.

Competitor comparison matrix
competitor or category	segment	overlap	request
Biofourmis / Current Health	RPM and virtual care	Monitoring, analytics, devices	Win/loss and pricing
Medable / trial platforms	Digital trials and RWE	Research workflows	Pipeline comparison
Internal enterprise builds	Build-versus-buy	Regulated health software	ROI and switching-cost proof

Basis-of-competition scoring
axis	public position	evidence strength	risk
Regulatory scope	FDA/EU/UK/Saudi claims	medium	Scope must be verified
Scale	3,000+ hospitals; 70+ countries	medium	Scale may not equal ARR
AI enablement	AI model hosting and 10x Nurse	medium	Model governance

Competitive positioning map Positioning by buyer and regulatory depth.

Chapter 05

05Marketing, Sales, and Distribution

The public GTM narrative emphasizes health systems, pharma, national projects and platform/SDK distribution; pipeline and sales productivity remain private gaps.

EC-003 EC-004 EC-010 EC-011 EC-012 EC-014 EC-013

V.A Strategy and implementation

partially verified confidence: medium

Public-source diligence for strategy and implementation is summarized with 2 linked table(s) and 1 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-003 EC-004 EC-010 EC-011

Evidence gaps

Company-provided source documents are required for checklist area V.A: Strategy and implementation.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for strategy and implementation.

Follow-up questions

Provide dated data-room materials covering strategy and implementation, with source-system exports where applicable.

Distribution channels and GTM motions
channel	public evidence	risk	request
Health systems	Hospitals/clinics, NHS and Banner signals	Procurement cycles	Pipeline and references
Pharma/life sciences	AstraZeneca, Bayer, Servier and top-pharma claims	Customer concentration	Contracts and revenue
Platform/SDK	Huma Cloud APIs/SDK	Developer adoption unknown	Usage data

Public marketing-signal summary
signal	message	caveat
Series D + Huma Cloud	Regulated platform launch	Validate product readiness
Regulatory claims	FDA and MDR status	Confirm scope
Case studies and quotes	Health-system/pharma references	Direct references needed

GTM channel signal mix Public signal count by GTM channel, not revenue.

V.B Major Customers

partially verified confidence: medium

Public-source diligence for major customers is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-004 EC-011 EC-012 EC-014

Evidence gaps

Company-provided source documents are required for checklist area V.B: Major Customers.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for major customers.

Follow-up questions

Provide dated data-room materials covering major customers, with source-system exports where applicable.

V.C Principal avenues for generating new business

partially verified confidence: medium

Public-source diligence for principal avenues for generating new business is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-010 EC-011

Evidence gaps

Company-provided source documents are required for checklist area V.C: Principal avenues for generating new business.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for principal avenues for generating new business.

Follow-up questions

Provide dated data-room materials covering principal avenues for generating new business, with source-system exports where applicable.

V.D Sales force productivity model

not publicly verifiable confidence: high

Public-source diligence for sales force productivity model is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-014

Evidence gaps

Company-provided source documents are required for checklist area V.D: Sales force productivity model.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for sales force productivity model.

Follow-up questions

Provide dated data-room materials covering sales force productivity model, with source-system exports where applicable.

V.E Ability to implement marketing plan with current and projected budgets

not publicly verifiable confidence: high

Public-source diligence for ability to implement marketing plan with current and projected budgets is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-013 EC-014

Evidence gaps

Company-provided source documents are required for checklist area V.E: Ability to implement marketing plan with current and projected budgets.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for ability to implement marketing plan with current and projected budgets.

Follow-up questions

Provide dated data-room materials covering ability to implement marketing plan with current and projected budgets, with source-system exports where applicable.

Chapter 06

06Research and Development

R&D signals center on Huma Cloud, regulated SaMD infrastructure, AI automation and research workflows; roadmap maturity and cost are not public.

EC-005 EC-018 EC-004 EC-010

VI.A Description of R&D organization

partially verified confidence: medium

Public-source diligence for description of r&d organization is summarized with 1 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-005 EC-018

Evidence gaps

Company-provided source documents are required for checklist area VI.A: Description of R&D organization.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for description of r&d organization.

Follow-up questions

Provide dated data-room materials covering description of r&d organization, with source-system exports where applicable.

R&D personnel and leadership signals
person or role	public role	evidence	request
Dan Vahdat	Founder and CEO	Quoted in Huma announcements	Key-person and equity review
Dr Mert Aral	Chief Medical Officer	Quoted in FDA clearance announcement	Clinical governance review
AI/model team	R&D/product automation	Google and other AI model partners	Org, model ownership and validation

VI.B New Product Pipeline

partially verified confidence: medium

Public-source diligence for new product pipeline is summarized with 1 linked table(s) and 1 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-004 EC-005 EC-010 EC-018

Evidence gaps

Company-provided source documents are required for checklist area VI.B: New Product Pipeline.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for new product pipeline.

Follow-up questions

Provide dated data-room materials covering new product pipeline, with source-system exports where applicable.

Public product and research pipeline
project	status	evidence	request
Huma Cloud	Launched/announced 2024	No-code, SDK, marketplace, AI hosting	Customer adoption
10x Nurse / AI automation	Roadmap signal	Google and others	Model validation
RWE and studies	Ongoing	800+ studies and about 1M participants	Study contracts

R&D and product portfolio map Public roadmap modules.

Chapter 07

07Management and Personnel

Public sources identify founder/CEO Dan Vahdat, CMO Dr Mert Aral, London HQ and global operations, but complete org and headcount are not public.

EC-005 EC-020 EC-008 EC-009 EC-019

VII.A Organization Chart

partially verified confidence: medium

Public-source diligence for organization chart is summarized with 0 linked table(s) and 1 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-005 EC-020

Evidence gaps

Company-provided source documents are required for checklist area VII.A: Organization Chart.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for organization chart.

Follow-up questions

Provide dated data-room materials covering organization chart, with source-system exports where applicable.

Public organization chart Public leadership and gaps.

VII.B Historical and projected headcount by function and location

partially verified confidence: medium

Public-source diligence for historical and projected headcount by function and location is summarized with 1 linked table(s) and 1 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-008 EC-009 EC-020

Evidence gaps

Company-provided source documents are required for checklist area VII.B: Historical and projected headcount by function and location.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for historical and projected headcount by function and location.

Follow-up questions

Provide dated data-room materials covering historical and projected headcount by function and location, with source-system exports where applicable.

Headcount and hiring signals
topic	public signal	status	request
Geography	Four continents; London HQ	verified	Headcount by location
Distributed work	Many roles not constrained by geography	partially_verified	Remote employment compliance
Headcount forecast	Not public	not_publicly_verifiable	Hiring plan and HRIS export

Headcount and geography anchors Public geography anchors and headcount gap.

VII.C Senior management biographies

partially verified confidence: medium

Public-source diligence for senior management biographies is summarized with 1 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-005 EC-008

Evidence gaps

Company-provided source documents are required for checklist area VII.C: Senior management biographies.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for senior management biographies.

Follow-up questions

Provide dated data-room materials covering senior management biographies, with source-system exports where applicable.

Senior management roster
name	role	evidence	request
Dan Vahdat	Founder and CEO	Huma announcements	Bio, ownership, employment agreement
Dr Mert Aral	Chief Medical Officer	Huma FDA announcement	Clinical governance
Other executives	Not fully public in reviewed sources	No complete roster found	Org chart and bios

VII.D Compensation arrangements

not publicly verifiable confidence: high

Public-source diligence for compensation arrangements is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-019 EC-020

Evidence gaps

Company-provided source documents are required for checklist area VII.D: Compensation arrangements.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for compensation arrangements.

Follow-up questions

Provide dated data-room materials covering compensation arrangements, with source-system exports where applicable.

VII.E Incentive stock plans

not publicly verifiable confidence: high

Public-source diligence for incentive stock plans is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-019 EC-020

Evidence gaps

Company-provided source documents are required for checklist area VII.E: Incentive stock plans.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for incentive stock plans.

Follow-up questions

Provide dated data-room materials covering incentive stock plans, with source-system exports where applicable.

VII.F Significant employee relations problems, past or present

not publicly verifiable confidence: high

Public-source diligence for significant employee relations problems, past or present is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-008 EC-020

Evidence gaps

Company-provided source documents are required for checklist area VII.F: Significant employee relations problems, past or present.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for significant employee relations problems, past or present.

Follow-up questions

Provide dated data-room materials covering significant employee relations problems, past or present, with source-system exports where applicable.

VII.G Personnel Turnover

not publicly verifiable confidence: high

Public-source diligence for personnel turnover is summarized with 1 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-020

Evidence gaps

Company-provided source documents are required for checklist area VII.G: Personnel Turnover.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for personnel turnover.

Follow-up questions

Provide dated data-room materials covering personnel turnover, with source-system exports where applicable.

Departures and employee-relations signals
topic	public signal	status	request
Executive departures	No schedule found	not_publicly_verifiable	Two-year departure list
Compensation/incentives	Not public	not_publicly_verifiable	Option and compensation plans

Chapter 08

08Legal and Related Matters

Public legal/regulatory evidence confirms active UK company status and Huma-claimed regulated SaMD status; counsel-grade review remains essential.

EC-016 EC-017 EC-001 EC-005 EC-007 EC-003 EC-011 EC-019

VIII.A Pending lawsuits against the Company

not publicly verifiable confidence: high

Public-source diligence for pending lawsuits against the company is summarized with 1 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-016

Evidence gaps

Company-provided source documents are required for checklist area VIII.A: Pending lawsuits against the Company.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for pending lawsuits against the company.

Follow-up questions

Provide dated data-room materials covering pending lawsuits against the company, with source-system exports where applicable.

Pending lawsuits against Huma
matter	public status	status	request
Material lawsuits	None found in reviewed sources	inconclusive	Counsel-grade docket search
Privacy/product/employment claims	Not publicly verifiable	not_publicly_verifiable	Legal claims schedule

VIII.B Pending lawsuits initiated by Company

not publicly verifiable confidence: high

Public-source diligence for pending lawsuits initiated by company is summarized with 1 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-016

Evidence gaps

Company-provided source documents are required for checklist area VIII.B: Pending lawsuits initiated by Company.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for pending lawsuits initiated by company.

Follow-up questions

Provide dated data-room materials covering pending lawsuits initiated by company, with source-system exports where applicable.

Pending lawsuits initiated by Huma
matter	public status	status	request
Company-initiated lawsuits	None found in reviewed sources	inconclusive	Counsel-grade search
IP/contract enforcement	Not public	not_publicly_verifiable	Legal schedule

VIII.C Environmental and employee safety issues and liabilities

inconclusive confidence: low

Public-source diligence for environmental and employee safety issues and liabilities is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-017

Evidence gaps

Company-provided source documents are required for checklist area VIII.C: Environmental and employee safety issues and liabilities.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for environmental and employee safety issues and liabilities.

Follow-up questions

Provide dated data-room materials covering environmental and employee safety issues and liabilities, with source-system exports where applicable.

VIII.D Material patents, copyrights, licenses, and trademarks

partially verified confidence: medium

Public-source diligence for material patents, copyrights, licenses, and trademarks is summarized with 1 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-001 EC-005 EC-007 EC-017

Evidence gaps

Company-provided source documents are required for checklist area VIII.D: Material patents, copyrights, licenses, and trademarks.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for material patents, copyrights, licenses, and trademarks.

Follow-up questions

Provide dated data-room materials covering material patents, copyrights, licenses, and trademarks, with source-system exports where applicable.

Material IP and regulated assets
asset	jurisdiction	status	request
Huma SaMD platform	United States	FDA Class II clearance claimed	FDA record and labeling
Regulated platform	EU/UK/Saudi Arabia	MDR/MHRA/Saudi claims	Certificates and audit reports
Huma brands/product names	Global commercial use	Trademark schedule not verified	IP schedule

VIII.E Insurance coverage and material exposures

not publicly verifiable confidence: high

Public-source diligence for insurance coverage and material exposures is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-016 EC-017

Evidence gaps

Company-provided source documents are required for checklist area VIII.E: Insurance coverage and material exposures.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for insurance coverage and material exposures.

Follow-up questions

Provide dated data-room materials covering insurance coverage and material exposures, with source-system exports where applicable.

VIII.F Material contracts

not publicly verifiable confidence: high

Public-source diligence for material contracts is summarized with 0 linked table(s) and 0 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-001 EC-003 EC-011 EC-019

Evidence gaps

Company-provided source documents are required for checklist area VIII.F: Material contracts.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for material contracts.

Follow-up questions

Provide dated data-room materials covering material contracts, with source-system exports where applicable.

VIII.G Regulatory agency problems

partially verified confidence: medium

Public-source diligence for regulatory agency problems is summarized with 1 linked table(s) and 2 linked figure(s). Private company records are required for investment reliance where public sources are incomplete.

EC-005 EC-016 EC-017

Evidence gaps

Company-provided source documents are required for checklist area VIII.G: Regulatory agency problems.

Hidden risks

Undisclosed contracts, customer economics, regulatory correspondence or operating data could materially change the diligence view for regulatory agency problems.

Follow-up questions

Provide dated data-room materials covering regulatory agency problems, with source-system exports where applicable.

Regulatory and agency action summary
agency or regime	status	date or period	request
Companies House	Active private company	2011-present	Full filing review
US FDA	Class II SaMD clearance claimed	2023	FDA record and post-market obligations
EU MDR / UK MHRA / Saudi FDA	Regulated status claimed	2024 materials	Certificates and correspondence
Privacy/security regulators	No enforcement schedule found	Current	DPIAs and incidents

Legal and regulatory timeline Public legal/regulatory milestones.

Risk heatmap Principal diligence risks.

Evidence

Evidence claims
ID	Claim	Status	Sources
EC-001	Huma is an active UK private limited company incorporated on 2 August 2011.	verified high	SRC-003
EC-002	CB Insights lists Huma at a $1B valuation dated 07/16/2024.	verified medium	SRC-001
EC-003	Huma announced over $80M Series D-related share issuance and over $300M raised to date.	verified high	SRC-002
EC-004	Huma publicly claims deployment scale across hospitals, users, studies and countries.	partially verified medium	SRC-002
EC-005	Huma received US FDA Class II clearance for a disease-agnostic SaMD platform.	partially verified high	SRC-006
EC-006	Huma says the SaMD platform can monitor patients of all ages and integrate third-party devices.	partially verified medium	SRC-006
EC-007	Huma publicly positions itself as a regulated AI and digital-first health platform.	verified medium	SRC-004 SRC-008 SRC-009 SRC-010 SRC-011
EC-008	Huma was founded in London in 2011 and operates across multiple geographies and four continents.	verified medium	SRC-005
EC-009	Huma HQ is in Millbank Tower, Westminster, London and distributed work is publicly described.	verified medium	SRC-005
EC-010	Huma Cloud is described as no-code/SDK-enabled regulated digital-health infrastructure.	partially verified medium	SRC-002
EC-011	Huma publicly cites strategic relationships and partner/customer quotes.	partially verified medium	SRC-004
EC-012	Huma disclosed a US respiratory RPM product covering 140,000 contracted lives.	partially verified medium	SRC-002
EC-013	Huma said revenue doubled year-on-year and targeted profitability in 2024, but audited financials are not public.	partially verified medium	SRC-002
EC-014	Customer revenue concentration, pricing, churn and contract economics are not publicly verifiable.	not publicly verifiable high	SRC-002 SRC-004
EC-015	Huma competes across RPM, digital therapeutics, decentralized trials and enterprise health AI.	inconclusive low	SRC-015
EC-016	No material litigation or enforcement schedule was found in reviewed public sources.	inconclusive low	SRC-003 SRC-007
EC-017	Huma has a multi-jurisdiction regulatory footprint.	partially verified medium	SRC-002 SRC-006 SRC-007
EC-018	Huma public R&D roadmap includes AI model development and a 10x Nurse concept.	partially verified medium	SRC-002
EC-019	Detailed cap table, debt, option pool, preference stack and off-balance sheet obligations are not public.	not publicly verifiable high	SRC-002 SRC-003
EC-020	Public pages do not disclose detailed headcount, turnover, compensation or incentive plan data.	not publicly verifiable high	SRC-005

Sources
ID	Publisher	Title	Accessed
SRC-001	CB Insights	CB Insights - The Complete List Of Unicorn Companies	2026-06-17
SRC-002	Huma	Huma completes Series D with over $80m financing and launches Huma Cloud Platform	2026-06-17
SRC-003	UK Companies House	HUMA THERAPEUTICS LIMITED overview	2026-06-17
SRC-004	Huma	Huma homepage	2026-06-17
SRC-005	Huma	About Huma	2026-06-17
SRC-006	Huma	Huma US FDA 510(k) Class II SaMD clearance announcement	2026-06-17
SRC-007	Huma	Huma quality and regulatory page	2026-06-17
SRC-008	Huma	Huma Workspace product page	2026-06-17
SRC-009	Huma	Huma Intelligence product page	2026-06-17
SRC-010	Huma	Huma A&E eTriage product page	2026-06-17
SRC-011	Huma	Huma GDm Health product page	2026-06-17
SRC-012	Huma	Huma emergency care case study	2026-06-17
SRC-013	Huma	Huma real-world evidence case study	2026-06-17
SRC-014	DuckDuckGo	DuckDuckGo snippets for Huma Series D and near-$1B valuation	2026-06-17
SRC-015	DuckDuckGo	DuckDuckGo snippets for Huma competitor categories	2026-06-17

Disclaimer

This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.